Stock report · Delisted · Nasdaq
Poseida Therapeutics Inc (PSTX)
9.50USD Delisted Final close · Jan 7, 2025
PSTX no longer trades. Poseida Therapeutics was delisted from the Nasdaq in January 2025.
All prices on this page are historical. The last trade was on January 7, 2025, at $9.50.
PSTX stock price history
Final trading statistics
- Final close
- $9.50
- Final trading day
- Jan 7, 2025
- Market cap at delisting
- $925.93M
- Shares outstanding
- 97.47M
- Final 52-week range
- $1.87 – $9.67
- Avg. volume (final 3 mo.)
- 1,694,304
- All-time high
- $16.25 · Jul 2020
- All-time low
- $1.62 · Aug 2023
- Return since IPO
- -38.1%
- Beta
- 0.54
- Book value / share
- $0.90
- Price / book
- 10.61
About Poseida Therapeutics Inc
Poseida Therapeutics, Inc. was a clinical-stage biopharmaceutical company building treatments for patients with serious unmet needs. In blood cancers, its candidates included P-BCMA-ALLO1 in Phase I for relapsed or refractory multiple myeloma and P-CD19CD20-ALLO1 in Phase I for B cell cancers and autoimmune diseases. P-BCMACD19-ALLO1, an off-the-shelf allogeneic CAR-T, and P-CD70-ALLO1 were in preclinical work.
For solid tumors, P-MUC1C-ALLO1 was in Phase I for breast, colorectal, lung, ovarian, pancreatic and kidney cancers. For metastatic castrate resistant prostate cancer (mCRPC), it had P-PSMA-ALLO1 in preclinical work and P-PSMA-101 in a Phase 1 trial.
The company also had clinical-stage liver-directed gene therapies: P-FVIII-101 for hemophilia A, P-OTC-101 for ornithine transcarbamylase deficiency and P-PAH-101 for phenylketonuria. It held a research and license deal with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Incorporated in 2014 and based in San Diego, California, it became a subsidiary of Roche Holdings, Inc. as of January 7, 2025. The stock was delisted from the Nasdaq that month, last trading on January 7, 2025 at $9.50.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA
- Employees
- 350
- IPO date
- July 10, 2020
- Delisted
- January 7, 2025
- SEC CIK
- 1661460
Poseida Therapeutics financials before the delisting
The last 5 fiscal years Poseida Therapeutics reported as a public company, fiscal year ending December.
PSTX revenue and net income
PSTX earnings per share
PSTX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $64.70M | −$123.4M | −$1.39 |
| FY2022 | $130.36M | −$64.0M | −$1.09 |
| FY2021 | $31.2K | $4.4M | −$2.02 |
| FY2020 | $0.00 | $2.5M | −$4.93 |
| FY2019 | $0.00 | −$92.6M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Poseida Therapeutics stock FAQ
What happened to Poseida Therapeutics stock?
Poseida Therapeutics was delisted from the Nasdaq in January 2025. The final close was $9.50 on January 7, 2025.
Can I still buy PSTX stock?
No. PSTX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on January 7, 2025.
What was the last price of PSTX?
PSTX last closed at $9.50 on January 7, 2025, which valued the company at about $925.93M.
How did Poseida Therapeutics do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Poseida Therapeutics reported revenue of $64.70M and net income of −$123.4M.
When did Poseida Therapeutics go public?
Poseida Therapeutics shares started trading on July 10, 2020.
PSTX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.